• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pediatrix Medical Group Inc. (Amendment)

    2/9/23 12:01:00 PM ET
    $MD
    Hospital/Nursing Management
    Health Care
    Get the next $MD alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 PEDIATRIX MEDICAL GROUP INC COMMON STOCK Cusip #58502B106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #58502B106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,439 Item 6: 0 Item 7: 12,310 Item 8: 0 Item 9: 12,310 Item 11: 0.014% Item 12: HC Cusip #58502B106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 12,310 Item 8: 0 Item 9: 12,310 Item 11: 0.014% Item 12: IN Item 1(a). Name of Issuer: PEDIATRIX MEDICAL GROUP INC Item 1(b). Address of Issuer's Principal Executive Offices: 1301 Concord Terrace Sunrise, FL 33323 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 58502B106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 12,310 (b) Percent of Class: 0.014% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 12,310 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PEDIATRIX MEDICAL GROUP INC. No one other person's interest in the COMMON STOCK of PEDIATRIX MEDICAL GROUP INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of PEDIATRIX MEDICAL GROUP INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $MD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MD

    DatePrice TargetRatingAnalyst
    12/16/2024Outperform
    Macquarie
    9/26/2024$8.00 → $14.00Hold → Buy
    Jefferies
    6/7/2024$8.00Sell → Hold
    Deutsche Bank
    2/23/2022$32.00 → $31.00Outperform
    Credit Suisse
    12/22/2021$33.00 → $32.00Outperform
    Credit Suisse
    11/4/2021$29.00 → $27.00Market Perform
    SVB Leerink
    9/27/2021$29.00Market Perform
    SVB Leerink
    8/9/2021$30.00 → $32.00Neutral
    Mizuho
    More analyst ratings

    $MD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pediatrix Medical Group Reports First Quarter Results

      Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f

      5/6/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group 2025 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 6, 2025

      Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across

      4/21/25 7:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group Reports Fourth Quarter Results

      Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited

      2/20/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, GC, Chief Admin Off & Sec Moore Mary Ann E gifted 26,497 shares, decreasing direct ownership by 21% to 100,338 units (SEC Form 4)

      4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

      3/7/25 5:00:10 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • EVP, CFO and Treasurer Rossi Kasandra H covered exercise/tax liability with 3,718 shares, decreasing direct ownership by 7% to 51,151 units (SEC Form 4)

      4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

      3/4/25 5:00:09 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • EVP, GC, Chief Admin Off & Sec Moore Mary Ann E covered exercise/tax liability with 8,975 shares, decreasing direct ownership by 7% to 126,835 units (SEC Form 4)

      4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

      3/4/25 5:00:17 PM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pediatrix Medical Group Inc.

      SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)

      11/13/24 4:30:24 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pediatrix Medical Group Inc.

      SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)

      10/31/24 11:54:57 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • SEC Form SC 13G/A filed by Pediatrix Medical Group Inc. (Amendment)

      SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)

      6/10/24 12:43:02 PM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Macquarie initiated coverage on Pediatrix Medical Group

      Macquarie initiated coverage of Pediatrix Medical Group with a rating of Outperform

      12/16/24 7:46:05 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group upgraded by Jefferies with a new price target

      Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously

      9/26/24 7:37:57 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00

      6/7/24 8:14:20 AM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Financials

    Live finance-specific insights

    See more

    $MD
    SEC Filings

    See more
    • Pediatrix Medical Group Reports First Quarter Results

      Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f

      5/6/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group 2025 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 6, 2025

      Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, May 6, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended March 31, 2025. A detailed press release will be issued the morning of May 6, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across

      4/21/25 7:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group Reports Fourth Quarter Results

      Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited

      2/20/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)

      5/8/25 4:30:14 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • SEC Form 10-Q filed by Pediatrix Medical Group Inc.

      10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)

      5/6/25 7:00:19 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Medical Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)

      5/6/25 6:50:08 AM ET
      $MD
      Hospital/Nursing Management
      Health Care

    $MD
    Leadership Updates

    Live Leadership Updates

    See more
    • Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Value Creation

      Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex

      1/13/25 6:00:00 AM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • Pediatrix Board Appoints Sylvia Young as Independent Director

      Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu

      5/4/23 4:05:00 PM ET
      $MD
      Hospital/Nursing Management
      Health Care
    • BurgerFi Appoints Vivian Lopez-Blanco to its Board of Directors

      PALM BEACH, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ:BFI, BFIIW))) ("BurgerFi" or the "Company"), one of the nation's fastest-growing premium fast-casual concepts, has appointed Vivian Lopez-Blanco to its board of directors, effective July 14, 2021. Lopez-Blanco's appointment follows the sudden passing of board member Steven Berrard announced on June 10, 2021. Lopez-Blanco has also been named as the chair of the audit committee and will be serving on the compensation committee and nominating governance committee. Lopez-Blanco is an experienced board member and seasoned finance executive with expertise in organizational transformations and driving prof

      7/15/21 7:30:00 AM ET
      $BFI
      $TAST
      $MD
      Restaurants
      Consumer Discretionary
      Hospital/Nursing Management
      Health Care